AUS
NZ
UK
CA
USA
IND
Healthcare
Three UK Stocks Highlighted for Possible Undervaluation of Up to 40.3%
October 24, 2024 09:57 AM BST| By Team Kalkine MediaHighlights,Market Downturn,: The UK stock market, including the FTSE 100 and FTSE 250, has faced recent declines influenced by weak trade data from China, affecting companies reliant on its economy.,Identifying Opportunities,: Amidst market challenge...
Avacta Showcases Promising Preclinical Results for AVA6103 and AVA7100 at 2024 EORTC-NCI-AACR Symposium
October 24, 2024 08:04 AM BST| By Team Kalkine MediaHighlights,Targeted Tumor Therapy,: AVA6103 and AVA7100 demonstrated strong preclinical results, focusing on tumor-specific drug delivery through FAP cleavage.,Reduced Toxicity,: Both therapies show promise in minimizing off-target effects and optimi...
Syncona’s Spur Therapeutics Reports Promising Phase I/II Data for FLT201 Gene Therapy in Gaucher Disease
October 23, 2024 03:10 PM BST| By Team Kalkine MediaHighlights,Positive Phase I/II Results for FLT201,: Spur Therapeutics presented encouraging data from the GALILEO-1 study, where five out of six patients treated with FLT201, a gene therapy for Gaucher disease, showed promising efficacy results.,Favo...
Scancell Holdings (AIM) Names Dr. Phil L'Huillier as CEO, Boosting Development Expertise
October 23, 2024 02:49 AM BST| By Team Kalkine MediaHighlights:,Dr. Phil L'Huillier appointed as CEO of Scancell (LSE), bringing extensive biotech expertise.,Current CEO, Professor Lindy Durrant, transitions to chief scientific officer and continues on the board.,Scancell is expecting significant data...
Earnings Performance of Genus (LON:GNS) Shows Promising Signs
October 22, 2024 09:29 AM BST| By Team Kalkine MediaHighlights:,Genus plc reported weak earnings recently, but a deeper analysis suggests the results may not fully reflect the company’s profitability potential.,The UK£48 million expense attributed to unusual items significantly impacted statutory prof...
Faron Pharmaceuticals Pursues Partnerships for Bexmarilimab Development
October 22, 2024 08:45 AM BST| By Team Kalkine MediaHighlights:,Faron Pharmaceuticals is seeking partnerships,to fund phase III development of its cancer drug, bexmarilimab.,Promising data from the BEXMAB trial,shows a 79% response rate in treating relapsed and refractory myelodysplastic syndrome (MDS...
Genflow Biosciences (LSE:GENF) Secures €4 Million Funding to Advance Gene Therapy for MASH
October 22, 2024 08:45 AM BST| By Team Kalkine MediaHighlights:,Genflow Biosciences (LSE:GENF) secures over €4 million in funding from Wallonia to advance its lead gene therapy, GF-1002.,The package includes a €1.2 million grant and a €2.8 million recoverable advance, supporting the development of MAS...
Scancell Holdings (LSE:SCLP) Appoints Dr Phil L'Huillier as New CEO
October 22, 2024 08:45 AM BST| By Team Kalkine MediaHighlights:,Scancell Holdings (LSE:SCLP) appoints Dr Phil L'Huillier as CEO, effective November 18.,Dr L'Huillier brings 30 years of experience in cancer immunotherapy and pharmaceutical development.,Professor Lindy Durrant will transition to focus s...
Genflow is Awarded Non-Dilutive Financial Support
October 22, 2024 08:12 AM BST| By Team Kalkine MediaHighlights:,Genflow Biosciences secures over €4 million in non-dilutive financial support from the Wallonia region for GF-1002 development.,The funding will facilitate the advancement of GF-1002, a gene therapy aimed at treating Metabolic Associated...
AstraZeneca's Treatment for Nerve Damage Advocated for EU Approval
October 21, 2024 09:47 AM BST| By Team Kalkine MediaHighlights,AstraZeneca's Wainzua nerve damage treatment has received a recommendation for approval from the European Medicines Agency (EMA).,The treatment, known as eplontersen, is already approved in the US for adults with hereditary transthyretin-m...
Wainzua Recommended for EU Approval: A Potential Breakthrough for hATTR-PN Treatment
October 21, 2024 08:45 AM BST| By Team Kalkine MediaHighlights:,Wainzua recommended for EU approval as the first self-administered treatment for hereditary transthyretin-mediated amyloidosis.,Phase III NEURO-TTRansform trial shows significant improvements in neuropathy impairment and quality of life.,...
Merck's RSV Treatment Shows Promising Results in Latest Clinical Trial
October 18, 2024 06:38 PM BST| By Team Kalkine MediaHighlights:,Positive Clinical Trial Results:,Merck's clesrovimab reduces RSV-related hospitalizations by over 84% in a mid-to-late-stage trial.,No Major Side Effects:,The treatment showed no significant adverse effects while reducing respiratory infe...
Despite a 28% Decline, Inspiration Healthcare Group plc (LON:IHC) Shows Positive Screening Results, Though Risks May Be Present
October 18, 2024 09:52 AM BST| By Team Kalkine MediaHighlights:,Inspiration Healthcare Group plc shares have declined by 28% in the past month, contributing to a significant 55% loss over the last twelve months.,The company's price-to-sales (P/S) ratio stands at 0.4x, considerably lower than the indus...
Oncimmune's Recapitalisation Efforts Lead to a 7% Gain in Share Price
October 18, 2024 09:37 AM BST| By Team Kalkine MediaHighlights:,Oncimmune Holdings PLC has experienced a 7% increase in share price following a successful fundraising initiative and debt restructuring.,The company is set to raise a minimum of £2 million through a share placing, board subscription, and...
Weight Loss Drugs Like Ozempic Could Curb Alcohol, Opioid Addiction
October 17, 2024 02:35 PM BST| By Team Kalkine MediaHighlights:,Study Findings,: GLP-1 drugs like Ozempic were linked to a 40% lower rate of opioid overdoses and a 50% reduction in alcohol intoxication among users.,Substance Abuse Impact,: The study tracked over 1.3 million individuals with alcohol an...
A stock decline of 11% this week has led to a 78% loss for shareholders in BATM Advanced Communications
October 17, 2024 08:45 AM BST| By Team Kalkine MediaHighlights:,BATM Advanced Communications Ltd. has seen a dramatic 78% decline in share price over the past three years, raising concerns among shareholders.,The company's earnings per share (EPS) has fallen significantly, contributing to the drop in...
Avacta Group Expands Oncology Pipeline with Two Novel Preclinical Assets: AVA6103 and AVA7100
October 17, 2024 08:38 AM BST| By Team Kalkine MediaHighlights,Avacta has added two new preclinical oncology assets, AVA6103 and AVA7100, to its pipeline, utilizing its pre|CISION® technology.,AVA6103 targets tumors with exatecan, a potent antitumor drug, while reducing its systemic toxicities.,AVA710...
Feedback PLC Secures Key NHS Funding for Bleepa Platform, Shares Surge Over 55%
October 16, 2024 12:01 PM BST| By Team Kalkine MediaHighlights:,NHS Funding Boost,: Feedback’s Bleepa platform becomes eligible for reimbursement under the NHS Elective Recovery Fund.,Strategic Partnership,: Partnership with Moorhouse Consulting to accelerate Bleepa’s implementation across NHS organis...
Image Scan Secures £3 Million Deal with NP Aerospace for Portable X-ray Systems
October 16, 2024 11:57 AM BST| By Team Kalkine MediaHighlights:,Major Contract Secured,: Image Scan Holdings signed a £3 million deal with NP Aerospace for its portable X-ray systems.,Long-term Revenue Impact,: The contract is expected to positively impact revenues in 2025 and 2026.,Share Price Surge,...
Graft Polymer Partners with University of Nottingham to Research New Mental Health Therapeutics
October 15, 2024 08:58 AM BST| By Team Kalkine MediaKey Points:,Graft Polymer and Awakn Life Sciences have partnered with the University of Nottingham to study the potential of an aminoindane new chemical entity (NCE) in enhancing social cognition for trauma-related disorders.,Led by Dr. Madeleine Kin...
